- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Real World Benefit Related to Improving Corneal Staining
Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses why the results showing improvement in both symptoms and signs with switching from Restasis (cyclosporine ophthalmic emulsion 0.05%) to Cequa (cyclosporine ophthalmic solution 0.09%) have real-world relevance.
He notes that in practice, both patients and doctors use symptoms as an overall indicator of treatment success. Symptom relief matters greatly in determining real-world effectiveness.
As for signs, improving corneal staining is important because this directly impacts blurry vision, which is a major frustration for patients. Even after otherwise successful cataract or refractive surgery, persisting corneal staining from dry eye can cause blurred vision and patient dissatisfaction.
By demonstrating the ability to improve both symptoms and vision-blurring corneal signs in incomplete Restasis responders switched to Cequa, study results offer meaningful real-world benefits.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
